Article
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $53
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $64 to $53.
Comments
- No comments yet. Be the first to comment!